Literature DB >> 11566321

The immunization of A2/K(b) transgenic mice with the KMP11-HSP70 fusion protein induces CTL response against human cells expressing the T. cruzi KMP11 antigen: identification of A2-restricted epitopes.

C Marañón1, M C Thomas, L Planelles, M C López.   

Abstract

Cytotoxic T lymphocyte response against Jurkat-A2/K(b) cells expressing the T. cruzi KMP11 protein has been evaluated after immunization of C57BL/6-A2/K(b) transgenic mice with the KMP11 and KMP11-HSP70 recombinant proteins. The results show that mice immunized with KMP11 covalently fused to the T. cruzi HSP70 protein, but not mice immunized with KMP11 alone, elicit a CTL response against the Jurkat-A2/K(b) cells expressing the KMP11 protein. The data also show that spleen cells from mice immunized with the fusion protein and stimulated with the K1 peptide induce lysis of both the Jurkat-A2/K(b) cells transfected with the KMP11 coding gene and the Jurkat-A2-K(b) cells pulsed with the K1 peptide. Splenocytes stimulated with the K3 peptide induce lysis of the Jurkat-A2/K(b) cells loaded with the K3 peptide but they do not recognize the target cells expressing the KMP11 protein. Similar results were obtained using lymph node from mice immunized with the peptides. Thus, we believe there are two cytotoxic T cell epitopes restricted to the A2 molecule (K1(KMP11) (4-12) and K3(KMP11) (41-50)) in the KMP11 protein, and suggest that the K1 peptide could be considered an immunodominant antigen whilst the K3 peptide may be regarded as a cryptic epitope. The fact that the CTL lines induced in B6-A2/K(b) mice recognize human cells expressing KMP11 protein, indicates that the KMP11 antigen fused to HSP70 could be a good candidate for the induction of immunoprotective cytotoxic responses against T. cruzi natural infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566321     DOI: 10.1016/s0161-5890(01)00059-1

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

1.  Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.

Authors:  Nisha Garg; Rick L Tarleton
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

Review 2.  Mini-chaperones: potential immuno-stimulators in vaccine design.

Authors:  Azam Bolhassani; Sima Rafati
Journal:  Hum Vaccin Immunother       Date:  2012-10-29       Impact factor: 3.452

3.  Differential phenotypic and functional profiles of TcCA-2 -specific cytotoxic CD8+ T cells in the asymptomatic versus cardiac phase in Chagasic patients.

Authors:  Adriana Egui; M Carmen Thomas; Bartolomé Carrilero; Manuel Segovia; Carlos Alonso; Concepción Marañón; Manuel Carlos López
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

4.  Immunogenicity and Efficacy of Live L. tarentolae Expressing KMP11-NTGP96-GFP Fusion as a Vaccine Candidate against Experimental Visceral Leishmaniasis Caused by L. infantum.

Authors:  Vahid Nasiri; Abdolhossein Dalimi; Fatemeh Ghaffarifar; Azam Bolhassani
Journal:  Iran J Parasitol       Date:  2016 Apr-Jun       Impact factor: 1.012

5.  An Animal Model of Acute and Chronic Chagas Disease With the Reticulotropic Y Strain of Trypanosoma cruzi That Depicts the Multifunctionality and Dysfunctionality of T Cells.

Authors:  Jose Mateus; Paula Guerrero; Paola Lasso; Claudia Cuervo; John Mario González; Concepción J Puerta; Adriana Cuéllar
Journal:  Front Immunol       Date:  2019-04-26       Impact factor: 7.561

Review 6.  T Cell Specificity: A Great Challenge in Chagas Disease.

Authors:  Fátima Ferragut; Gonzalo R Acevedo; Karina A Gómez
Journal:  Front Immunol       Date:  2021-06-29       Impact factor: 7.561

7.  Promiscuous Recognition of a Trypanosoma cruzi CD8+ T Cell Epitope among HLA-A2, HLA-A24 and HLA-A1 Supertypes in Chagasic Patients.

Authors:  Paola Lasso; Lina Beltrán; Fanny Guzmán; Fernando Rosas; M Carmen Thomas; Manuel Carlos López; John Mario González; Adriana Cuéllar; Concepción J Puerta
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.